anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine. ^ SUBSTANCE: invention belongs to medicine, notably to surgery and resuscitation, and can be used as intestinal distention preventing method in patients with widespread peritonitis. For this purpose on Th10-12-LI vertebrae level mixture of medications is injected subdermally. Mixture consists of 6 ml of 0.5% marcaine solution, 16 IE of lydasum, 0.5 ml of 0.05% proserin. Injection is made once a day for five days. ^ EFFECT: method allows preventing the intestinal distention by affecting the spinal cord nervous structures, which form abdominal and mesenteric plexus, promoting its metabolism and motility recovering. ^ 1 ex
PURPOSE: Timothy syndrome (TS) is characterized by congenital long-QT arrhythmia and limb syndactyly. Patients who undergo syndactyly repair with undiagnosed TS may have their abnormal cardiac electrical activity unmasked during surgery. The purpose of this study was to detail the extremity phenotype seen in patients with TS, which may help hand surgeons in their preoperative assessment.
METHODS: This was a retrospective review of all patients with TS seen at our institution from 1998 to 2022. Descriptive statistics regarding their demographics, medical and surgical histories, and syndactyly phenotypes were obtained.
RESULTS: Seven patients (5 males and 2 females) with TS were seen at our institution for multidisciplinary evaluation (median age at presentation was 23 months). Six patients had finger syndactyly and 5 had toe syndactyly. One patient did not have any extremity syndactyly and was noted to have a specific TS mutation known to lack musculoskeletal abnormalities. All patients with finger syndactyly had border digit involvement, with 5 out of 6 patients displaying syndactyly of the middle-ring and ring-little finger web spaces. Toe syndactyly was more heterogeneous, with 1 patient lacking any lower extremity syndactyly and others having variable involvement of the second-third, third-fourth, and fourth-little toe web spaces. Complexity ranged from simple to complete. Four patients had intraoperative cardiac events leading to TS diagnoses after surgery.
CONCLUSIONS: Bilateral border digit hand syndactyly, with or without bilateral toe syndactyly, should raise concerns for TS and prompt further investigation into potential cardiac disease to avoid perioperative cardiac morbidity and mortality.
TYPE OF STUDY/LEVEL OF EVIDENCE: Therapeutic V.
The invention provides a health-care health-preserving tea capable of reinforcing the kidney, supporting yang, benefiting eyes and improving eyesight. The health-care health-preserving tea is prepared from Anhua dark tea, dodder, wolfberry fruit, broomrape, cornel and raspberry according to the principle of mutual benefits. The health-care health-preserving tea maintains the original subtle fragrance and palatability of the tea, and enhances the health-preserving function of the compound tea. The conversion of the inherent substances in the tea and the interactions of the microbial metabolites constitute the material basis of the unique health-care function of the Anhua dark tea. After being drunk, the health-care health-preserving tea has the effects of reinforcing the kidney, supporting yang, benefiting eyes, improving eyesight, tonifying the liver and the kidney, securing essence and reducing urination. The health-care health-preserving tea is suitable for people with deficiency of the kidney, lumbago, impotence and seminal emission, frequent micturition, infertility because of cold wombs, poor night vision, deficiency of liver-yin and kidney-yin, premature senility and dry faces with wrinkles.
At registration, subjects will be mailed a questionnaire. The subject will then receive two separate dignity therapy sessions; the first session will take place about 6 weeks after registration, with the second session occurring 1-3 weeks after the first. Subjects will then be asked to complete a questionnaire about one month after completing therapy sessions.
The primary objective of this exploratory project is to evaluate the safety and efficacy of a highly viscous, water-soluble fiber supplement, glucomannan, for achieving weight loss in overweight and moderately obese individuals. Overweight and obesity are major public health problems in the U.S. that account for substantial morbidity, mortality, and healthcare costs. Conventional approaches to weight loss are largely ineffective, particularly for long-term weight loss and maintenance. Thus, there is a critical need for safe and effective adjunctive treatments. A few, limited studies suggest that glucomannan supplementation is associated with weight loss, is well-tolerated, and has a favorable safety profile.

In this preliminary study, the target population will be overweight and moderately obese individuals, a population that accounts for nearly 50% of all U.S. adults. The specific aims of the project are to: 1) describe the safety of glucomannan for achieving weight loss in overweight and moderately obese individuals, and 2) describe the efficacy of glucomannan for achieving weight loss in overweight and moderately obese individuals. Participants will take glucomannan supplements daily for eight weeks in a double-blind, placebo-controlled, randomized clinical trial. Safety and efficacy outcome measures include: gastrointestinal symptoms/tolerance, hepatic panel, serum creatinine, weight, body composition, diet intake, hunger/fullness, lipid profile, blood glucose, and C-reactive protein. Examination of the safety and efficacy of glucomannan for achieving weight loss will extend our understanding of additional treatments that may be effective in combating a significant public health problem.
The present invention relates to a preparation technology and a production method for an integrated new formulation of a snakegourd root-oyster powder, wherein the raw materials of active ingredients comprise: 10 parts by weight of snakegourd root, and 10 parts by weight of oyster. The production process of the integrated new formulation of snakegourd root-oyster powder comprises the following steps of: supersonic air-jet crushing, alcohol-water extraction, ultrasonic crushing extraction, water decocting concentration, supersonic spray drying, nanometer grinding, high pressure homogenization, nano particle preparation and the like. According to the invention, the advantages, such as multi-synergism, multi-target, embodied by a nano-carrier coupling technique, are focused to be taken of. After the integrated new formulation of snakegourd root and oyster powder is subjected to scale production, the production cost can be greatly reduced, the quality of products is greatly improved and the targeting property and the sustained and controlled release performance of the medicament are enhanced. The internal and external administration of the integrated new formulation of snakegourd root and oyster powder can be realized simultaneously, and can be respectively taken in four time slices according to midnight-noon ebb-flow and qi and blood flowing rule of a human body. The integrated new formulation of snakegourd root and oyster powder can be further prepared into films and transdermal agents which are respectively stuck to different parts of a human body according to the midnight-noon ebb-flow and qi and blood flowing rule of the human body and can be directly absorbed through skin.
This study will evaluate the pharmacokinetic linearity of a single 35 mg fenofibric acid dose and demonstrate the bioequivalence of three 35 mg fenofibric acid tablets (105 mg total single dose) to a single 105 mg fenofibric acid tablet in healthy adult volunteers when each dose is administered under fasted conditions. Fifty-four healthy, non-smoking, non-obese, 18-45 year old, male and female volunteers will be randomly assigned in a crossover fashion to receive each of three fenofibric acid dosing regimens in sequence with a 7 day washout period between dosing periods. On the morning of the first day of each dosing period, after an overnight fast of at least 10 hours, subjects will receive single doses of fenofibric acid (1 x 35 mg tablet), fenofibric acid (3 x 35 mg tablets - 105 mg total dose), or fenofibric acid (1 x 105 mg tablet). Fasting will continue for 4 hours after dose administration. Blood samples will be drawn from all participants prior to dosing and for 72 hours post-dose, at times sufficient to adequately define fenofibric acid pharmacokinetics. Subjects will be monitored throughout their participation for adverse reactions to the study drug and/or procedures. Seated blood pressure and pulse will be measured prior to each dose and approximately 2 hours after each dose to coincide with peak plasma concentrations. All adverse experiences, whether elicited by query, spontaneously reported, or observed by clinic staff, will be documented in the subject's case report form.
PURPOSE:To remove immune complex from blood, plasma, or other body fluids, by contacting the plasma, etc. with an anti-human immunogloblin Fc fragment antibody immobilized to a carrier. CONSTITUTION:An anti-human immunoglobulin Fc fragment antibody is immobilized to a carrier, and placed in a container. Blood, plasma or other body fluid containing immune complex is introduced into the container by a transfer means, and the immune complex is bonded with the anti-human immunoglobulin Fc fragment antibody supported on the carrier. After the removal of the immune complex, the blood, plasma or other body fluid is collected from the container. The anti-human immunoglobulin antibody can be prepared by hydrolyzing human immunoglobulin (IgG, IgM, IgA, IgE, or IgD) with a proteinase such as papain, treating the product by column purification, and immunizing an animal with the resultant Fc fraction component.
Subjects will receive a single, oral dose (1 tablet) of Placebo each morning with food for 12 weeks. All subjects will be provided vaginal lubricant (K-Y® Brand) and should use it as needed.
NEW MATERIAL:N-Benzoylmefenamic acid expressed by formula I. USE:A hyaluronidose activity inhibitor having inhibitory action on hyaluronidase activity and useful as an antiallergic and antiulcer agent. PREPARATION:Mefenamic acid expressed by formula II or a reactive derivative at the amino group thereof is reacted with benzoic acid or a reactive derivative at the carboxy group thereof, or group R in a compound expressed by formula III(R is a derivative of the carboxy group) is converted to give the aimed compound expressed by formula I. The former reaction is carried out usually in a solvent, e.g. dioxane, under heating. A method usually used for eliminating the protecting group of the carboxy group, e.g. hydrolysis or reduction, is applied to the latter reaction. The hydrolysis includes acidic and basic hydrolyses.
IRT is based on affect regulation theories of binge eating and adds emphasis on cognitive restructuring techniques. IRT is a 10 session, group-based, guided-self-help treatment that works to decrease binge eating by primarily enhancing emotion coping skills, in addition to transforming faulty interpretations and reducing vulnerabilities (e.g., interpersonal events) that risk overwhelming emotion and problematic cognitions.
Waist circumference (WC) is an easy and reliable measure of visceral adipose tissue and a simple index of cardiovascular risk. The World Health Organization (WHO) reported sex specific WC cut off values for the Caucasian people, named as action levels 1 and 2, to define the overweight or obese people. These cut off values, originally established in a Dutch population, were later adopted by several medical organizations in order to define Metabolic Syndrome. However, these cut off levels may not necessarily represent the characteristics of the other populations. Therefore it is recommended that the sex specific WC cut off points should be established for different ethnic groups.

The investigators aimed to investigate whether the suggested sex specific WC cut off points for the Caucasian adults are appropriate for the Turkish adult population. The secondary aim of the study is to search for better WC cut off points to predict obesity, metabolic syndrome and increased cardiovascular risk in Turkish adult men and women.
Lobsters and crayfish in Australasia can develop a condition known as Tail Fan Necrosis (TFN syndrome). Many attempts have been made to find a primary pathogen or link the syndrome to commercial activities, but a solution remains elusive. TFN syndrome is a 'wicked problem', a problem difficult or impossible to solve because of incomplete and contradictory information forming a matrix of potential outcomes with no simple solution. Reviewing the literature shows TFN syndrome is sometimes reported to develop in association with sterile blisters on the telson and uropods which may rupture permitting invasion by environmental fungal and/or bacterial flora. Whether blisters form prior to, or because of, infection is unknown. TFN syndrome sometimes develops in captivity, sometimes requires a previous insult to the telson and uropods, and prevalence is patchy in the wild. The literature shows the cause of blisters associated with TFN syndrome remains an enigma, for which we suggest several possible initiating factors. We strongly urge that researchers not 'jump to conclusions' as to the aetiology of TFN syndrome. It cannot be explained without carefully exploring alternative aetiologies whilst being cognisant of the age-old lesson that 'correlation does not equal causation'.
<P>PROBLEM TO BE SOLVED: To provide a DNA encoding a therapeutically suitable glutaminase, a polypeptide having a therapeutically suitable glutaminase activity and their use in antiviral and anticancer therapy.  <P>SOLUTION: The DNA encoding the therapeutically suitable glutaminase has been molecularly cloned. This allows one to obtain a polypeptide which is a therapeutically suitable glutaminase free of contaminating endotoxin. It has been found that this polypeptide is a potent anti-viral agent and is a potent anti-cancer agent when coupled to an anti-tumor monoclonal antibody. The glutaminase of the present invention is particularly useful for treating lung, breast and colon cancer cells and in the treatment of HIV-infected cells.  <P>COPYRIGHT: (C)2004,JPO
The number of high-risk patients undergoing non-cardiac surgery has increased continuously over the last two decades. There is a paucity of data exist about the bioavailability of postoperative administrated beta-blockers. One study reported adequate plasma levels of Propanolol after administration via nasogastric tube but not after oral administration in patient undergoing thyroid surgery.Thus it is possible that patients maintained on oral beta blockers may in fact be experiencing a withdrawal syndrome. Because of the importance of avoiding withdrawal of beta blockers, intravenous administration may be the only alternative in cases where oral administration fails to achieve adequate plasma levels perioperatively. Furthermore, due to changes in pharmacodynamics, intravenous dosage may be the optimal way to achieve tight hemodynamic control. There is, however, no data on the post-operative hemodynamic effects of orally administered beta blockers in patients on chronic beta blockers.
Participants will complete 12 sessions (20 minutes of walking on a treadmill) over a 6-8 week period while receiving audiovisual biofeedback based on the muscle activity of their ankle plantarflexors. The visual feedback will be provided on a screen with a bar showing real-time muscle activity and the audio feedback will be a sound played when they reach the target level of muscle activity.
Participants will receive SBRT (8 Gy × 3-5 fractions) to all visible lesions. Systemic treatment (tislelizumab and regorafenib) will start concurrently and last for 2 years, or until disease progression, intolerable side-effects or death. Tislelizumab will be delivered every 21 days at a dose of 200mg, and regorafenib will be given at a dose of 120mg for the first 21 days of a 28-day cycle. Appropriate dose adjustments of regorafenib will be made if side-effects are intolerable, while the dose of tislelizumab should not be adjusted, but could be paused.
Cervical cancer is the major cause of cancer deaths among women in Nepal. Screening is one of the most effective tools for early diagnosis, prevention, and treatment. However, skilled health professionals and tools available for cervical cancer screening are limited in low and middle-income countries (LMICs) including Nepal. The World Health Organization (WHO) and Alliance for Cervical Cancer Prevention (ACCP) recommends that countries, areas, or institutions seeking to initiate or strengthen cervical cancer screening programs should consider introducing or expanding Visual Inspection with Acetic acid (VIA) until more appropriate and affordable HPV-based tests become available. 'National Guideline for Cervical Cancer Screening and Prevention in Nepal, 2010' includes VIA as a screening method for cervical cancer. Current studies reveal Nepalese women's participation in cervical cancer screening is low. Thus, there is a need for appropriate, cost-effective and sustainable interventions to increase VIA screening uptake at the primary health care level across Nepal.

The primary objective of this study is to evaluate the effect of a Female Community Health Volunteer (FCHV) led community-based educational intervention through home visits increasing cervical cancer screening uptake. The primary outcome of the study is to increase the cervical cancer-screening uptake in the intervention group. This will be the first community-based cluster-randomized trial designed to mobilize FCHVs for increasing cervical cancer screening uptake in Nepal.
Introduction: Stress urinary incontinence (SUI) is defined by involuntary loss of urine. According to the literature, its prevalence ranges from 30 to 60%. The first-line treatment of SUI is pelvic floor muscle training (PFMT). The assessment of pelvic floor muscle (PFM) contraction is essentially clinical, based on the modified OXFORD system associated with symptom questionnaires. Ultrasound is more widely used in case of SUI but has never been evaluated before and after PFMT.

Objective: The main objective of this study will be to carry out a validation study of ultrasound measurements in women with predominant SUI (urethral mobility, movement of the ano-rectal angle, elastography): Inter/intra-observer reproducibility; variability versus measurement by correlation with clinical examination (modified Oxford scale); sensitivity to change before/after PFMT Secondary objectives will be to show a correlation between the different ultrasound measurements and the clinical symptoms assessed by validated questionnaires : International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF) and Contilife. A quantitative pulseal elastography analysis by Ultra-fast shear wave elastography (Supersonic Imagine) will also be performed before and after PFMT, looking for changes after PFMT. We Patient satisfaction after PFMT will also be assessed using the validated "Patient Global Impression of Improvement" questionnaire (PGI-I) Materials and Methods: This is a single-center prospective study involving patients in PFMT for predominant SUI. Patients will have a 10-week PFMT protocol. An evaluation will be conducted at the beginning and end of the program. This will include an assessment of symptoms using validated questionnaires (ICIQ-SF, CONTILIFE), a clinical examination (modified Oxford scale), as well as transperineal ultrasound measurements of urethral mobility (Bladder Neck Desent, BND measured in centimeters), movement of ano-rectal angle and quantitative elastography measurements (Ultra-fast shear wave, elasticity E expressed in kiloP).
The interventional group will be given audiovisual equipment. An Apple iPad will be attached to a Mayo stand and placed approximately 12-15 inches from the patient's face. Noise canceling headphones will be connected to the iPad. A movie of the subject's choosing will be shown on the iPad with a comfortable level of sound.
FIELD: chemistry of polymers. SUBSTANCE: present invention describes polymeric composition, especially composition of absorption material or biologically active agent-containing depositing material consisting essentially of water-soluble and/or polysaccharide-based polymer capable of being swollen in water as main component (A) and water swollen polymer as other component (B) as polymeric composite parts and also matrix material to prevent stratification and gel blocking, ionic or covalent cross-linking agent, reactive additive, and antiblocking agent. Component (B) includes polymer and/or copolymer of metacrylic acid, metacrylonitrile, metacrylamide, vinyl acetate, vinyl pyrrolidone, vinyl pyrrolidine, maleic acid, maleic anhydride, itaconic acid, rthaconic acid, itaconic anhydride, fumaric acid, vinyl sulfonic acid and/or 2- acrylamido-2-methylpropane sulfonic acid. Polymeric composition and absorbent prepared by simple procedure are biodegradable, have comparatively high rate and capacity as they absorb water and aqueous solutions. EFFECT: improved properties of the polymeric composition. 27 cl, 13 ex
This is a Phase 2a randomized, masked, placebo-controlled clinical trial to evaluate the safety and efficacy of Xiflam for use in patients with signs/symptoms of Long COVID. Patients will be randomized to Xiflam the study drug (n=10) or Placebo (n=5). Both Xiflam and Placebo will be taken once daily by mouth for 12 weeks.

I. Baseline Screening Visit After obtaining informed consent and before treatment is initiated, an initial study visit will be conducted in person to confirm subject eligibility. Subjects will be asked complete a baseline questionnaire to assess signs and symptom severity. During this screening visit, a baseline blood sample will be obtained to determine any changes over time in any of the measured parameters. These include biomarkers of inflammation. Additional study procedures occurring during the baseline/screening phase of this study are outlined in the protocol. Patients who are found not to meet inclusion criteria, will not be entered into the treatment Phase of the study.
The purpose of this study is to determine whether CBT124 and Avastin® are comparable in terms of efficacy, safety, immunogenicity; and whether the pharmacokinetics of CBT124 matches that of Avastin® (pharmacokinetics is nested in this study for Indian patients). To test the clinical equivalence in terms of efficacy and safety, a two-sided test approach based on a pre-specified range to test the null hypothesis that the proposed biosimilar is either (1) inferior to the reference product or (2) superior to the reference product based on the pre-specified equivalence margin will be used. The equivalence margins are chosen to enable detection of clinically meaningful differences in effectiveness between CBT124, candidate biosimilar bevacizumab and reference product (EU-sourced Avastin®) at the 95% confidence interval (CI). In this trial, asymmetric equivalence margins will be used, i.e., the upper (superiority) and the lower (inferiority) bounds of the equivalence margin are not symmetric. The goal is to reject the null hypothesis of non-equivalence and accept the alternative hypothesis that the two treatments (in this case, CBT124 and EU-sourced Avastin®) are equivalent (i.e., the differences between the two are not clinically and statistically meaningful). The hypothesis testing will be performed by determining if the difference in the primary end point (Objective Response Rate \[ORR\]) between the reference product (EUsourced Avastin®) and proposed biosimilar (CBT124) is within the equivalence margin at the 95% CI.